Italian wealthy families seed startups, while fintech businesses keep raising funds.
Finscience, an Italian big data startup operating in the field of financial analysis, is launching a second capital increase after having raised one million of euros last November (see here a previous post by BeBeez). Fabrizio Milano D’Aragona, the company’s ceo, Mauro Arte, Claudio Zamboni, and Alessandro Arrigo, the firm’s general manager, founded Finscience. The company raised its first round fundraising from seasoned finance professional such as Giuseppe Galimberti, a former banker of JP Morgan, Morgan Stanley, Deutsche Bank, and UBS; Ugo Pastori, managing partner of Weisstor and former ceo of hedge fund Thalia. The list of investors also includes Massimo Prelz Oltramonti, a former managing director of Advent International;Marco Belmondo and Guido Ferrarini, two of the owners of Epic sim; Nicola Colla and Fabio Nalucci co-founders of Gellify.
Exor, the listed financial holding of the Agnelli Family, and its portfolio company PartnerRe invested in 11 US tech startups 20 million of US dollars through Exor Seeds a venture firm with left resources worth 100 million (see here a previous post byBeBeez). Noam Ohama heads Exor Seeds, an investor with a longer investment perspective than traditional venture capital firms.
Bruno Farmaceutici, an Italian producer for anti dyabete drugs, invested 75k euros in InSilico Trials, an Italian SMEs which has developed a web platform for clinical trials that adopts simulations and algorithms instead of experiments with patients that is raising equity through the equity crowdfunding portal CrowdFundMe (see here a previous Post by BeBeez). Insilico Trials platform allows pharmaceutical companies to reduce by 50% R&D timing. The company is currently collaborating with FDA and EMA, the US and EU drug agencies. Insilico Trials raised 0.239 million overachieving its 0.15 million target with a pre-money valuation of 9.4 million.
